Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

Fintel reports that on January 17, 2025, UBS downgraded their outlook for Charles River Laboratories International (NYSE:CRL) ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.

UBS downgrades Charles River Laboratories (CRL) to neutral citing concerns about decelerating sales growth, lowers price target to $185. Read more here.

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

William Blair downgraded Charles River (CRL) to Market Perform from Outperform.Invest with Confidence: Follow TipRanks' Top Wall Street ...

This was the stock's second consecutive day of losses.

UBS Group reaffirmed their neutral rating on shares of Charles River Laboratories International (NYSE:CRL – Free Report) in a research note released on Friday morning, MarketBeat reports. They ...

William Blair reaffirmed their outperform rating on shares of Charles River Laboratories International (NYSE:CRL – Free Report) in a research report report published on Tuesday,Benzinga reports. A ...